Search

Your search keyword '"Nortje H"' showing total 24 results

Search Constraints

Start Over You searched for: Author "Nortje H" Remove constraint Author: "Nortje H"
24 results on '"Nortje H"'

Search Results

1. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

2. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis

3. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis

4. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

5. Dapagliflozin and cardiovascular outcomes in type 2 diabetes

6. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

7. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

8. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

9. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

10. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics

11. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial

12. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial

13. Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

14. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

15. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

16. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME (R) trial

17. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF

18. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

19. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial

20. Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

22. Alogliptin after acute coronary syndrome in patients with type 2 diabetes

23. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

24. A 24-week, prospective, randomized, open-label, treat-to-target pilot study of obese type 2 diabetes patients with severe insulin resistance to assess the addition of exenatide on the efficacy of u-500 regular insulin plus metformin.

Catalog

Books, media, physical & digital resources